文献速递消化、代谢与肾脏急症

伐尼克兰联合尼古丁贴片及延长疗程对戒烟效果的影响:一项随机临床试验

Effects of Combined Varenicline With Nicotine Patch and of Extended Treatment Duration on Smoking Cessation: A Randomized Clinical Trial.
PubMed 文献 · JAMA · 2021-01-01
一句话结论在每日吸烟≥5支的成人中,伐尼克兰联合尼古丁贴片对比单药、或24周对比12周疗程,52周7天点流行戒烟率均无显著差异。

这项双盲2×2析因随机临床试验在两家诊所纳入1251名每日吸烟≥5支的成人,随机接受伐尼克兰单药12周、伐尼克兰联合尼古丁贴片12周、伐尼克兰单药24周或联合24周,均接受戒烟咨询。主要终点为52周时一氧化碳确认的7天点流行戒烟率。24周 vs 12周戒烟率24.8% vs 24.3%(RD -0.4%,95%CI -5.2%至4.3%);联合 vs 单药24.3% vs 24.8%(RD 0.4%,95%CI -4.3%至5.2%)。结论不支持联合治疗或延长疗程。

要点

  • 在每日吸烟≥5支的成人中,伐尼克兰联合尼古丁贴片对比伐尼克兰单药,52周7天点流行戒烟率无显著差异(24.3% vs 24.8%,RD 0.4%,95%CI -4.3%至5.2%)。
  • 延长伐尼克兰疗程至24周对比12周,52周戒烟率无显著差异(24.8% vs 24.3%,RD -0.4%,95%CI -5.2%至4.3%)。
  • 四组恶心发生率24.0%-30.9%,失眠发生率24.4%-30.5%。
  • 研究结论不支持联合伐尼克兰与尼古丁贴片或延长疗程至24周用于戒烟。

适用人群与场景

  • 每日吸烟≥5支的成人,来自美国威斯康星州麦迪逊和密尔沃基两家诊所,共1251人随机分组。

诊断标准与关键阈值

  • 主要终点为52周时一氧化碳确认的自我报告7天点流行戒烟。

处置流程与药物剂量

  • 所有参与者接受戒烟咨询,并随机分配至以下四组之一:伐尼克兰单药12周(n=315)、伐尼克兰联合尼古丁贴片12周(n=314)、伐尼克兰单药24周(n=311)、伐尼克兰联合尼古丁贴片24周(n=311)。
  • 原文未提及伐尼克兰及尼古丁贴片的具体剂量、给药途径、频次或目标值。

红旗征与不能漏的情况

  • 原文未提及

研究设计与关键结果

  • 双盲2×2析因随机临床试验,在美国2家诊所纳入1251名每日吸烟≥5支的成人,随机接受伐尼克兰单药12周、联合尼古丁贴片12周、单药24周或联合24周,均接受戒烟咨询。
  • 24周 vs 12周:24.8%(154/622) vs 24.3%(153/629),RD -0.4%(95%CI -5.2%至4.3%),OR 1.01(95%CI 0.89-1.15)。
  • 联合 vs 单药:24.3%(152/625) vs 24.8%(155/626),RD 0.4%(95%CI -4.3%至5.2%),OR 0.99(95%CI 0.87-1.12)。
  • 不良事件:恶心发生率24.0%-30.9%,失眠发生率24.4%-30.5%。
  • 751人(60.0%)完成治疗,881人(70.4%)提供最终随访。

证据类型、等级与局限

  • 证据类型:双盲2×2析因随机临床试验。
  • 局限:仅在美国2家诊所开展,完成治疗率60.0%,最终随访率70.4%;原文未提及证据等级或推荐强度。

对床旁实践的改变

  • 对于每日吸烟≥5支的成人,本研究结果不支持联合使用伐尼克兰与尼古丁贴片或延长伐尼克兰疗程至24周来增加戒烟率。
  • 原文未提及适用与不适用人群的进一步区分或常见陷阱。

指南或共识出处

  • 原文未提及指南或共识名称;试验注册号ClinicalTrials.gov NCT03176784。

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

IMPORTANCE: Smoking cessation medications are routinely used in health care. Research suggests that combining varenicline with the nicotine patch, extending the duration of varenicline treatment, or both, may increase cessation effectiveness.

OBJECTIVE: To compare combinations of varenicline plus the nicotine or placebo patch vs combinations used for either 12 weeks (standard duration) or 24 weeks (extended duration).

DESIGN, SETTINGS, AND PARTICIPANTS: Double-blind, 2 × 2 factorial randomized clinical trial conducted from November 11, 2017, to July 9, 2020, at 1 research clinic in Madison, Wisconsin, and at 1 clinic in Milwaukee, Wisconsin. Of the 5836 adults asked to participate in the study, 1251 who smoked 5 cigarettes/d or more were randomized.

INTERVENTIONS: All participants received cessation counseling and were randomized to 1 of 4 medication groups: varenicline monotherapy for 12 weeks (n = 315), varenicline plus nicotine patch for 12 weeks (n = 314), varenicline monotherapy for 24 weeks (n = 311), or varenicline plus nicotine patch for 24 weeks (n = 311).

MAIN OUTCOMES AND MEASURES: The primary outcome was carbon monoxide-confirmed self-reported 7-day point prevalence abstinence at 52 weeks.

RESULTS: Among 1251 patients who were randomized (mean [SD] age, 49.1 [11.9] years; 675 [54.0%] women), 751 (60.0%) completed treatment and 881 (70.4%) provided final follow-up. For the primary outcome, there was no significant interaction between the 2 treatment factors of medication type and medication duration (odds ratio [OR], 1.03 [95% CI, 0.91 to 1.17]; P = .66). For patients randomized to 24-week vs 12-week treatment duration, the primary outcome occurred in 24.8% (154/622) vs 24.3% (153/629), respectively (risk difference, -0.4% [95% CI, -5.2% to 4.3%]; OR, 1.01 [95% CI, 0.89 to 1.15]). For patients randomized to varenicline combination therapy vs varenicline monotherapy, the primary outcome occurred in 24.3% (152/625) vs 24.8% (155/626), respectively (risk difference, 0.4% [95% CI, -4.3% to 5.2%]; OR, 0.99 [95% CI, 0.87 to 1.12]). Nausea occurrence ranged from 24.0% to 30.9% and insomnia occurrence ranged from 24.4% to 30.5% across the 4 groups.

CONCLUSIONS AND RELEVANCE: Among adults smoking 5 cigarettes/d or more, there were no significant differences in 7-day point prevalence abstinence at 52 weeks among those treated with combined varenicline plus nicotine patch therapy vs varenicline monotherapy, or among those treated for 24 weeks vs 12 weeks. These findings do not support the use of combined therapy or of extended treatment duration.

TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03176784.

来源:JAMA,查看原文。版权归原作者所有。

参考来源

  1. Baker TB, Piper ME, Smith SS, et al. Effects of Combined Varenicline With Nicotine Patch and of Extended Treatment Duration on Smoking Cessation: A Randomized Clinical Trial. JAMA. 2021. PMID: 34665204. doi:10.1001/jama.2021.15333

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。